Boston Scientific Acquires SoniVie for $540M, Expanding into Renal Denervation Market
• Boston Scientific has agreed to acquire SoniVie for up to $540 million, marking its strategic entry into the renal denervation market for treating resistant hypertension.
• SoniVie's Tivus intravascular ultrasound system, currently in global IDE trials, uses ultrasound energy to ablate renal artery nerves for improving kidney filtration.
• The acquisition follows recent FDA approvals of competing RDN systems from Recor Medical and Medtronic, indicating growing momentum in the renal denervation space.
© Copyright 2025. All Rights Reserved by MedPath